The coming of age of rapid ART initiation in HIV

Lack of insurance coverage, active injection drug use, patient and provider attitudes toward treatment and opportunistic infection testing are all obstacles to beginning treatment, as well as numerous other factors. Evidence supporting rapid initiation of ART Randomized trials in resourcelimited cou...

Full description

Saved in:
Bibliographic Details
Published in:Infectious Disease News 2019-11, Vol.32 (11), p.7-7
Main Author: Brock, Jeff
Format: Article
Language:English
Subjects:
Acquired immune deficiency syndrome
AIDS
Antiretroviral drugs
Disease transmission
Drug resistance
Drug therapy
HIV
Human immunodeficiency virus
Medical tests
Patients
Researchers
Retention
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lack of insurance coverage, active injection drug use, patient and provider attitudes toward treatment and opportunistic infection testing are all obstacles to beginning treatment, as well as numerous other factors. Evidence supporting rapid initiation of ART Randomized trials in resourcelimited countries have demonstrated that offering ART at the time of diagnosis results in earlier initiation of ART and higher rates of retention in care and viral suppression without compromising safety. Once the decision is made to start ART before genotypic or phenotypic resistance testing is available, the ART regimen should not include a nonnucleoside reverse transcriptase inhibitor because of concerns with transmitted drug resistance (K103N mutation), which could put the patient at risk for virologic failure.
ISSN:1056-9251